Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

[...] um pregnancy test, throughout the study duration, and until 46 yearsmonths after the last dose of radiation. Should a woman become pre [...]

[...] 5.0) =< grade 1 (except alopecia) at the time of enrollment Absolute neutrophil count >=1.5 x 10^9/L Hemoglobin >= 9 g/dL Platelets >= 100 x 10^9/L Total bilirubin =< 1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN Creatinine < 1.5 mg/dL or calculated creatinine clearance* >= 50 mL/min or 24- [...] >= 18 years old Non-small cell lung cancer (NSCLC), histolog [...] mittee on Cancer (AJCC) stage II-III NSCLC (T1-4N0-3M0) and select patients with stage IV oligometastatic disease. For patients with oligometastatic [...] isease (up to 5 total sites of [...]

Maximally tolerated dose (MTD) of papaverine (PPV) in combination with chemoradiation treatment (CRT) or definitive hypofractionated radiation therapy

[...] of papaverine (PPV) in combination with chemoradiation (CRT)/radiation andtherapy immunotherapy(RT) in patients with unresectable locally advanced (LA) non-small cell lung cancer (NSCLC) or oligometastatic NSCLC. SECONDARY OBJECTIVES: I. To estimate the rates of primary [...] ies can predict which patients may respond best to PPV + CRT/RT, and detect changes in oxygenation before and after PPV adm [...] ients receive PPV intravenously (IV) or subcutaneously (SC) over 30 minutes and patients receiving chemoradiation undergo 5 fractions of radiation therapy (RT) per week for 6 weeks or 5 fractions of hypofra [...] [...]

[...] (i.e. carboplatin + paclitaxel or carboplatin + pemetrexed) Women of childbearing potential are required to use an effective method of contraception from the time of negative serum pregnancy test, throughout the study duration, and until 4 years after the last dose of radiation. Should a woman become pregnant or suspect she is pregnant while she or her partn [...] Exclusion Criteria: Patients with history of pneumonectomy H [...]

[...] t Committee on Cancer (AJCC) stage II-III NSCLC (T1-4N0-3M0) and patients with oligometastatic disease. For patients with oligometastatic disease (up to 5 total sites of disease) for whom definitive chemoradiation to the primary and regional lymph nodes is recommended by the multidisciplinary team, each individual metastatic tumor would be considered an additional site of disease with the exception of [...] Patients must be considered unresectable or medically-inoperable Patients with a local or regional recurrence following surgical resection for whom definitive chemoradiation to disease in the ches [...] [...]

[...] ) and undergo 5 fractions of radiation therapy (RT) per week for 6 weeks. Patients also receive paclitaxel IV over 1 hour and carboplatin IV once weekly (QW) over 1-6 weeks or pemetrexed IV over 10 minutes followed by carboplatin IV every 3 weeks in the absence of disease progression or unacceptable toxici [...] se receive durvalumab IV every 2 weeks (Q2W) for 12 months. Patients also undergo positron emission tomography/computed tomography (PET/CT) or CT and brain magnetic resonance imaging (MRI) during screening, and blood sample collection and CT scans throughout the trial. Patients may also under [...] [...]